Tarloxotinib | 1636938-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: Tarloxotinib
• 英文别名: [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium
• CAS: 1636938-13-0
• 化学式: C24H24BrClN9O3+
• 分子量: 601.9
• InChiKey: MUJMYVFVAWFUJL-SNAWJCMRSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS
  申请人：The Regents of The University of Colorado, A Body Corporate

  公开号：EP3679063A1

  公开（公告）日：2020-07-15
• KINASE INHIBITOR PRODRUG FOR THE TREATMENT OF CANCER
  申请人：Auckland UniServices Limited

  公开号：US20170360790A1

  公开（公告）日：2017-12-21

  Compositions containing and methods of administering TH-4000 are useful in treatment of cancer alone or in combination with other anti-cancer agents.
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT OU DE PRÉVENTION DE CANCERS PHARMACORÉSISTANTS INDUITS PAR HER
  申请人：UNIV COLORADO REGENTS

  公开号：WO2019051155A1

  公开（公告）日：2019-03-14

  The present invention includes methods of treating or preventing HER-driven drug-resistant cancers. In certain embodiments, the cancer comprises lung cancer.